A Phase 2, Pilot, Multicenter, Randomized, Placebo-Contr

Project: Research project

Project Details


A Phase 2, Pilot, Multicenter, Randomized, Placebo-Controlled, Sequential, Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Activity of CC-930 in Subjects with Recalcitrant Discoid Lupus Erythematosus (DL
Effective start/end date3/1/122/28/14


  • Celgene Corporation

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.